ArticleOncotarget2025

A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment.

Maja Buszko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.